Brainomix appoints Khush F. Mehta as Chair to accelerate global ai healthcare expansion

In a move signaling its global ambitions in the medical AI space, Brainomix has appointed Khush F. Mehta as Chair of the Board to lead the company’s next phase of commercial expansion. This leadership transition, announced on May 21, 2025, comes amid heightened momentum for Brainomix, a University of Oxford spinout known for its AI-powered imaging platforms in stroke and lung disease. Mehta replaces Professor Jackie Hunter CBE, who successfully chaired the board for five years during a period of significant scaling and international reach.

Khush Mehta’s appointment arrives shortly after the company raised £14 million (approximately $18 million) in Series C funding. These proceeds are earmarked for expanding Brainomix’s market presence, particularly in the U.S., and advancing its flagship Brainomix 360 platform, which recently received FDA clearance for a new, patented feature.

Who Is Khush F. Mehta and What Does He Bring to Brainomix?

With over two decades of leadership in healthcare technology, Khush F. Mehta is widely respected for his strategic foresight and operational acumen. His most recent role was as Chairman of Arterys, an AI imaging pioneer later acquired by Tempus AI in 2022. Mehta also held critical roles at Siemens Healthcare, serving as Chief Strategy Officer and leading operations across the Asia Pacific, as well as posts in both the U.S. and Germany.

Mehta holds an MBA from Yale School of Management and a master’s degree in Commerce and Financial Management from Sydenham College in Mumbai. He is currently based in the United States, aligning with Brainomix’s growing focus on the North American healthcare market. His cross-continental experience, combined with deep domain knowledge in healthcare AI, positions him as an asset to Brainomix as it scales globally.

How Is Brainomix Positioned in the Global AI Imaging Market?

Brainomix has carved a reputation as a global leader in medical AI by developing clinically validated imaging biomarkers and AI-powered decision-support tools. The company’s Brainomix 360 stroke platform is widely regarded as one of the most comprehensive tools for stroke imaging, enabling faster and more effective treatment decisions across emergency and neurology departments.

The company’s expansion into lung fibrosis through its e-Lung platform reflects broader ambitions to diversify its AI portfolio across critical disease areas. With adoption in over 20 countries and commercial offices in the U.K., Ireland, and the U.S., Brainomix has evolved from a promising academic spinout into a robust, revenue-generating business backed by leading healthtech investors.

What Does the Series C Funding Enable for Brainomix?

The recent £14 million ($18 million) Series C funding round equips Brainomix with the financial runway to scale its commercial operations across international markets. Notably, this round comes at a time when U.S. hospital systems are accelerating the integration of AI to improve patient throughput, diagnostic accuracy, and cost efficiency in stroke care.

The funding is expected to support further R&D, commercial deployments, and strategic hiring in the U.S. and Europe. It also allows Brainomix to deepen its work in clinical partnerships, particularly with pharma companies and large hospital networks that seek integrated imaging solutions.

What Strategic Impact Has Jackie Hunter Had as Outgoing Chair?

Professor Jackie Hunter CBE concludes her five-year tenure having guided Brainomix through a formative period of evolution from start-up to international scale-up. Her time as Chair witnessed the doubling of company size, expansion into the U.S. and other key global markets, and the widespread adoption of the Brainomix 360 platform. Hunter played an instrumental role in securing partnerships with global pharmaceutical firms, positioning Brainomix at the intersection of AI innovation and life sciences collaboration.

Her tenure is noted for anchoring the company’s transition from a research-heavy entity to a commercial healthcare technology firm with a growing market footprint. Under her leadership, Brainomix’s technologies moved beyond the U.K. National Health Service (NHS) to broader markets, including U.S. hospital networks and pan-European health systems.

What Are Brainomix’s Core AI Products and Their Clinical Applications?

Brainomix’s product suite centers on precision medicine through AI-assisted imaging, with a heavy emphasis on stroke care and respiratory conditions like idiopathic pulmonary fibrosis (IPF). The flagship product, Brainomix 360, uses AI to support clinicians in evaluating stroke severity and guiding treatment paths such as thrombolysis or thrombectomy. This AI platform integrates multiple imaging biomarkers, streamlining complex decision-making in time-sensitive emergency settings.

The company’s emerging e-Lung platform applies similar principles to lung imaging, enabling early detection and monitoring of pulmonary diseases. These tools are especially relevant in regions facing physician shortages or where imaging interpretation consistency is critical for patient outcomes.

How Is Brainomix Scaling Commercial Operations in the U.S.?

The U.S. market, given its expansive healthcare infrastructure and openness to innovation, is a strategic priority for Brainomix. Khush Mehta’s U.S. base is a clear signal of intent to consolidate and expand commercial operations in the region. With FDA clearance already secured for key features in the Brainomix 360 platform, the company is now focused on converting regulatory milestones into sales traction through direct hospital partnerships and collaborations with U.S.-based healthtech vendors.

The appointment of Mehta also enables more nuanced engagement with payer systems, value-based care models, and digital health accelerators, many of which are unique to the American healthcare ecosystem. With reimbursement dynamics playing a pivotal role in AI adoption, Brainomix is likely to explore partnerships that validate clinical outcomes through real-world data in U.S. settings.

What Does Industry Sentiment Suggest About Brainomix’s Trajectory?

Analysts in the digital health sector view Brainomix as one of the more clinically mature and commercially ready AI imaging companies. Unlike many peers that remain in pilot or pre-commercial stages, Brainomix has demonstrated tangible impact across hundreds of hospitals and has successfully navigated complex regulatory environments in both Europe and North America.

The appointment of a U.S.-based Chair with both corporate and start-up experience is interpreted as a tactical move to bolster transatlantic growth. Investor sentiment, buoyed by the Series C round and regulatory milestones, reflects confidence in Brainomix’s execution capabilities. Several institutional investors are reportedly evaluating the company for follow-on funding or strategic partnerships, especially as AI adoption accelerates across integrated care delivery networks.

How Will Brainomix Navigate Competitive Pressures in Healthcare AI?

Brainomix operates in a highly competitive segment where major tech firms and healthcare conglomerates are pushing aggressively into AI imaging. However, its focus on clinically validated, disease-specific applications such as stroke and lung fibrosis offers a differentiated position compared to broader imaging tools.

Its success hinges on continuing to demonstrate outcome-based value, building long-term hospital and pharma relationships, and expanding its clinical evidence base. The hiring of Mehta, with a background in both start-up and enterprise environments, could help navigate this competitive complexity while preserving the agility of an innovation-first firm.

As Brainomix enters its next phase of growth, its ability to unify AI innovation with global commercialization strategy will be critical. With Khush F. Mehta steering the board, the company appears positioned to strengthen its standing in the AI healthcare landscape while advancing its mission to improve patient outcomes across geographies.